Between December 2024 and September 2025, the FDA issued more than 50 warning letters to companies selling peptide products. The letters are all on fda.gov. They show clear patterns in what the agency considers illegal marketing, and what happens to suppliers who think a "research use only" label covers them.
Here is what the letters actually say, with links to the originals so you can read them yourself.
The "Research Use Only" Defense Does Not Work
On December 10, 2024, the FDA sent a warning letter to Prime Vitality, Inc., which did business as Prime Peptides (MARCS-CMS 695156). The company sold semaglutide and retatrutide labeled "for research purposes only" and "not for human consumption." The FDA looked at their website, their Instagram, their Facebook, and their YouTube channel. Every single one of those channels made therapeutic claims.
Their blog post "Top Weight Loss Peptides: Semaglutide, Tirzepatide & More" talked about clinical trials and weight loss percentages. Their Instagram reposted customer testimonials. A YouTube video explained how the drugs work in the human body. The FDA said the "research use only" label did not matter. The company was selling unapproved new drugs under Section 505(a) of the FD&C Act.
The same day, the FDA sent nearly identical letters to Xcel Research LLC (xcelpeptides.com, MARCS-CMS 694608) and Summit Research Peptides (summitpeptides.shop, MARCS-CMS 695607). Both used the same pattern: research labels on the product, therapeutic marketing everywhere else.
Source: FDA Warning Letter 695156 \u2014 Prime Vitality/Prime Peptides
International Sellers Targeting the US Market
On February 26, 2025, the FDA warned USApeptide.com, a company based in Germany (MARCS-CMS 696885). The site sold semaglutide and tirzepatide to US customers without any prescription requirement. The FDA cited them for both unapproved new drug violations and misbranding.
The letter pointed out that the site also sold insulin syringes and bacteriostatic water alongside the peptides. The FDA said this "heightens the public health concern" because injectable products "bypass many of the body\u2019s natural defenses." They warned that products appearing to be misbranded "may be detained or refused admission" at the border.
Source: FDA Warning Letter 696885 \u2014 USApeptide.com
The September 2025 Wave: 50+ Letters at Once
In September 2025, the FDA sent more than 50 warning letters in a single wave, mostly dated September 9, 2025. This time the target was different: compounders who were calling their products "generic versions" of Ozempic, Wegovy, Mounjaro, and Zepbound.
The FDA said those claims are false. Compounded drugs are not evaluated by the FDA for safety, effectiveness, or quality. They are not the same as approved products, and calling them "generic" is misleading. Several letters also went after "proven effectiveness" and "real results" claims for weight loss.
Even Novo Nordisk and Eli Lilly received warning letters in this wave, over a prime-time TV special the FDA said created "a misleading impression regarding the safety" of their products.
Source: Wilson Sonsini on the FDA\u2019s 50+ Warning Letter Wave (October 1, 2025)
What This Means for Buyers
The warning letters are a free, searchable database on fda.gov. Before you commit to a supplier, search their name there. It takes five minutes.
The pattern across every letter is the same. There is a gap between what the supplier claims and what they can document. The suppliers that get letters:
- Sell products with disease-treatment claims but slap a "research only" label on them.
- Offer prescription drugs without requiring a prescription.
- Tell customers their compounded products are the same as FDA-approved brands.
- Cannot produce GMP documentation, batch records, or Certificates of Analysis from an accredited lab.
The suppliers that do not get letters operate under registered FDA establishments, maintain current GMP certifications, and provide lot-specific quality documentation. That is the difference.
A few practical rules for anyone sourcing peptide products commercially:
"Research use only" is not a legal category. It is a marketing disclaimer with no basis in the FD&C Act. The FDA looks at the totality of your marketing, not your label. If your supplier markets with therapeutic claims, they are outside compliance.
GMP certification matters. The FDA and EMA guidelines for synthetic peptides require documented impurity profiling, process validation, and quality systems. If a supplier cannot produce these documents, they represent supply chain risk.
Cross-border sourcing has specific legal risk. Import Alert 66-40 and the USApeptide.com letter show the FDA actively monitors foreign websites selling to US consumers.
The warning letter database is free. Search it before you buy. A history of warning letters is the strongest negative signal you can get without commissioning an audit.
References
- FDA Warning Letter 695156 \u2014 Prime Vitality, Inc. (Prime Peptides), December 10, 2024
- FDA Warning Letter 694608 \u2014 Xcel Research LLC, December 10, 2024
- FDA Warning Letter 696885 \u2014 USApeptide.com, February 26, 2025
- FDA Warning Letter Database
- Wilson Sonsini \u2014 FDA Sends Warning Letters to More Than 50 GLP-1 Compounders and Manufacturers (October 1, 2025)
- EMA Guideline on the Development and Manufacture of Synthetic Peptides
- FDA Guidance: ANDAs for Synthetic Peptide Drug Products (2021)